Track topics on Twitter Track topics that are important to you
Enzyvant, a Cambridge, MA-based rare disease drug developer, has appointed Jeb Ledell as its chief operating officer. Ledell previously held COO roles at Cambridge-based Compass Therapeutics and at Horizon Discovery Group, a genomics company in the UK. Enzyvant’s lead candidate, RVT-802, a regenerative treatment for pediatric congenital athymia, is expected to receive an FDA decision in […]
Original Article: Enzyvant Adds Compass’s Jeb Ledell as Its Chief Operating OfficerNEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...
Congenital conditions are those which are present from birth. They include structural deformities or loss of function in organs such as the <!--LGfEGNT2Lhm-->heart, gut or skeletal system. They can be corrected by <!--LGfEGNT2Lhm-->surgery, m...